Table 5.
Compounds in clinical trials targeting tau interactions with its PPIs.
| Name | Function | Phase (Disease) | Efficacy | Source |
|---|---|---|---|---|
| Dasatinib | Ab1 and Src kinase inhibitor | Phase I and II | Recruiting | NCT04063124 |
| Epigallocatechin gallate | DYRK1A kinase inhibitor | Phase II (AD) | No results posted | NCT00951834 |
| Lithium chloride | GSK-3 kinase inhibitor | Phase II (AD/PSP) | No effect |
NCT00088387 [605] |
| Nilotinib | Ab1 kinase inhibitor | Phase II (AD/PD) | Unknown |
NCT02947893 [606] |
| Saracatinib | Ab1, Src kinase inhibitor | Phase II (AD) | No effect |
NCT02167256 [607,608] |
| Tideglusib | GSK-3 kinase inhibitor | Phase II (AD/PSP) | No effect |
NCT01350362 [609,610,611,612] |
| Valproate | GSK-3 kinase inhibitor | Phase III (AD) | No effect |
NCT00071721 [613,614,615] |
| Memantine | PPP2CA activator | Phase IV (AD) | No effect |
NCT00469456 [616] |
| Sodium selenate | PPP2CA activator | Phase II (AD) | Small positive effects | [617] |
| Salsalate | Acetylation inhibitor | Phase I (AD/PSP) | Ongoing |
NCT03277573 [618] |
| Minocycline | CDK5 kinase/caspase-3 inhibitor | Phase II (AD) | No effect | NCT01463384 |
| Nicotinamide | HDAC inhibitor | Phase II | Recruiting | NCT03061474 |
| Phenylbutyrate | HDAC inhibitor | Phase II | Ongoing | NCT03533257 |
| Vorinostat | HDAC inhibitor | Phase I | Recruiting | NCT03056495 |